Abstract: The present disclosure relates to antibodies or antigen binding fragments thereof that specifically bind to Motile Sperm Domain Containing Protein 2 (MOSPD2) and methods of using the same.
Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.
Type:
Grant
Filed:
May 17, 2021
Date of Patent:
July 4, 2023
Assignee:
ALS THERAPY DEVELOPMENT INSTITUTE
Inventors:
John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
Abstract: Disclosed in the present invention are an antibody targeting LAG-3, a preparation method therefor and the use thereof. In particular, disclosed in the present invention is a novel monoclonal antibody targeting LAG-3. Also disclosed in the present invention is a method for the preparation of the monoclonal antibody. The monoclonal antibody of the present invention is capable of binding LAG-3 antigens with high specificity, and has very high affinity and significant activities such as anti-tumor activity.
Abstract: A B7-H3 antibody, an antigen-binding fragment thereof and a medical use thereof are provided. Furthermore, a pharmaceutical composition containing the B7-H3 antibody or antigen-binding fragment thereof, and the use thereof as a medicament are provided. In particular, a use of a human B7-H3 antibody or antigen-binding fragment thereof for the manufacture of a medicament for the treatment of a B7-H3-associated disease or condition are described.
Abstract: The present invention discloses a monoclonal antibody against nerve growth factor, and an encoding gene and use thereof. The monoclonal antibody against nerve growth factor of the present invention comprises heavy chains comprising a heavy chain constant region and a heavy chain variable region, and light chains comprising a light chain constant region and a light chain variable region. The heavy chain variable region comprises three complementarity determining regions HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises three complementarity determining regions LCDR1, LCDR2 and LCDR3.
Abstract: The combination of a first binding site specifically binding to a target associated with an eye disease and a second binding site specifically binding to a target influencing the retention in the eye a multispecific binder provides for improved intravitreal retention compared to a monospecific binder. The second binding site specifically binds to a compound/molecules found in the extracellular matrix (ECM) in vitreous humor/retina. This compound of the extracellular matrix has to be present in amounts allowing a sufficient loading/dose of the drug to be bound. It has been found that collagen, especially collagen II, is a suitable compound in the ECM in the vitreous humor for this purpose. Thus, herein is reported a multispecific binder comprising a first binding site specifically binding to a therapeutic ocular target, and a second binding site specifically binding to collagen II.
Abstract: The present invention is based, in part, on the discovery of galectin 1 (Gal1) epitopes against which anti-Gal1 agents can neutralize Gal1 function, as well as anti-Gal1 agents and methods useful for neutralizing Gal1 function.
Type:
Grant
Filed:
October 7, 2020
Date of Patent:
June 13, 2023
Assignee:
Dana-Farber Cancer Institute, Inc.
Inventors:
Margaret A. Shipp, Jing Ouyang, Scott J. Rodig
Abstract: Antibodies that bind specifically to glycosylated PD-L1 relative to unglycosylated PD-L1, block binding of PD-L1 to PD-1 and promote internalization and degradation of PD-L1 are provided. Antibodies that recognize specific epitopes on glycosylated PD-L1 protein and that exhibit the dual functions of both blocking the binding of PD-L1 to PD-1 and also facilitating the internalization of PD-L1 on cells are provided. In some aspects, PD-L1 polypeptides comprising glycosylated amino acid residues at amino and carboxy terminal positions of the PD-L1 extracellular domain are also provided. Methods for using such antibodies for the treatment of cancer, particularly PD-L1 positive cancer, are also provided.
Type:
Grant
Filed:
March 24, 2017
Date of Patent:
May 30, 2023
Assignees:
STCUBE, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Stephen S. Yoo, Ezra M. Chung, Yong-Soo Kim, Kyu Lee Han, Andrew H. Park, Mien-Chie Hung, Chia-Wei Li, Seung-Oe Lim
Abstract: The present disclosure provides anti-LAG-3 heavy-chain antibody or the antigen-binding domain thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.
Abstract: The present invention provides CTLA-4 monoclonal antibodies, particularly humanized monoclonal antibodies specifically binding to CTLA-4 with high affinity. The present invention also provides functional monoclonal antibodies cross-reactive to CTLA-4 of human, cynomolgus monkey and mouse. The present invention further provides amino acid sequences of the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. The epitopes of the antibodies are identified. Therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating cancers and other diseases with anti-CTLA-4 antibodies.
Abstract: Objective of the present invention is to provide a novel monoclonal antibody against Nav1.7. The present invention discloses a monoclonal antibody against Nav1.7 or its antibody fragment, having specific six CDRs (CDR1 to CDR3 of a heavy chain and CDR1 to CDR3 of a light chain) or specific heavy/light chain variable regions. The monoclonal antibody and the like can be used for treating or preventing pain, pruritus and so on.
Abstract: The present disclosure provides anti-?4?7 antibodies that bind human ?4?7, their methods of making, and their uses to treat patients with HIV infection.
Abstract: The disclosure discloses a preparation of type I collagen-like fibers and a method for regulating and controlling the periodic length of fiber stripes thereof, belonging to the technical field of genetic engineering. The disclosure produces a three-segment chimeric collagen P-CL-P pattern by inserting a continuous Gly-Xaa-Yaa triplet collagen sequence in the middle based on the N- and C-terminal (GPP)n sequences. The self-assembly is driven by the interaction between the N- and C-terminal (GPP)n triple helixes to form banded fibers with periodic bright and dark stripes. According to the method of the disclosure, a fiber from a clean source, which can self-assemble to form periodic bright and dark stripes can be prepared, the structure of which is similar to type I collagen, the preparation process is simple, the collagen fiber with low cost can be produced on a large scale, and the method has broad application prospects in the field of biological materials.
Type:
Grant
Filed:
October 28, 2020
Date of Patent:
May 2, 2023
Assignees:
JIANGNAN UNIVERSITY, RUTGERS UNIVERSITY
Inventors:
Fei Xu, Jinyuan Hu, Vikas Nanda, David I. Shreiber, Meng Zhang, Sonal Gahlawat
Abstract: Provided are anti-CD47 antibodies or fragments thereof that can bind to the extra cellular domain of the CD47 protein. The antibodies or fragments thereof can effectively block the interaction between human CD47 and its ligand SIRP alpha and enhance the phagocytosis activity of macrophages to engulf cancer cells. Some of these antibodies or fragments do not induce in vitro hemagglutination and therefore can be suitably used as therapeutic agents with reduced off-target effects.
Abstract: The present disclosure provides anti-OX40 antibodies, and antigen-binding portions thereof. In certain embodiments, the antibodies or fragments thereof, are used for the treatment of cancer.
Abstract: The present disclosure relates to antibodies that bind human CD19 (“anti-human CD19 antibodies” or “anti-human CD19 antibodies”), compositions comprising such anti-human CD19 antibodies, and methods of using such anti-human CD19 antibodies.
Type:
Grant
Filed:
February 22, 2021
Date of Patent:
April 11, 2023
Assignee:
Eli Lilly and Company
Inventors:
Barrett Allan, Jeffrey Streetman Boyles, Alison Lee Sim Budelsky, Kira Vladimirovna Rubtsova, Guifeng Zhang, Songqing Na
Abstract: The invention provides methods for treating patients with anti-?4?7 antibody comprising predicting outcome of the antibody therapy. The invention relates to the identification of patients who can respond to therapy comprising an anti-?4?7 antibody.
Type:
Grant
Filed:
June 27, 2019
Date of Patent:
March 7, 2023
Assignee:
Takeda Pharmaceutical Company Limited
Inventors:
Maria Rosario, Timothy L. Wyant, Brihad Abhyankar
Abstract: Provided herein are methods for alleviating symptoms in a subject having Rett syndrome, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D).
Type:
Grant
Filed:
June 21, 2021
Date of Patent:
March 7, 2023
Assignees:
VACCINEX, INC., The Sydney Children's Hospital Network
Inventors:
Yilin Mao, Wendy Gold, Elizabeth E. Evans, Maurice Zauderer